Voya Investment Management LLC lowered its holdings in MannKind Co. (NASDAQ:MNKD - Free Report) by 14.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 517,460 shares of the biopharmaceutical company's stock after selling 86,155 shares during the period. Voya Investment Management LLC owned about 0.19% of MannKind worth $3,327,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of MNKD. Price T Rowe Associates Inc. MD boosted its stake in MannKind by 12.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 175,009 shares of the biopharmaceutical company's stock valued at $1,126,000 after acquiring an additional 18,806 shares during the last quarter. Dark Forest Capital Management LP raised its stake in MannKind by 71.1% during the fourth quarter. Dark Forest Capital Management LP now owns 34,975 shares of the biopharmaceutical company's stock valued at $225,000 after buying an additional 14,528 shares in the last quarter. Hsbc Holdings PLC grew its position in shares of MannKind by 49.7% in the 4th quarter. Hsbc Holdings PLC now owns 31,327 shares of the biopharmaceutical company's stock worth $203,000 after acquiring an additional 10,407 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of MannKind by 441.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 30,693 shares of the biopharmaceutical company's stock valued at $197,000 after acquiring an additional 25,025 shares during the last quarter. Finally, MetLife Investment Management LLC raised its position in shares of MannKind by 3.3% during the 4th quarter. MetLife Investment Management LLC now owns 158,481 shares of the biopharmaceutical company's stock valued at $1,019,000 after acquiring an additional 5,110 shares in the last quarter. Institutional investors and hedge funds own 49.55% of the company's stock.
MannKind Trading Down 0.1 %
NASDAQ:MNKD traded down $0.01 during midday trading on Wednesday, hitting $4.78. 217,558 shares of the stock were exchanged, compared to its average volume of 2,374,098. The business has a 50-day moving average price of $4.92 and a two-hundred day moving average price of $5.86. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of 68.21 and a beta of 1.14. MannKind Co. has a one year low of $4.17 and a one year high of $7.63.
MannKind (NASDAQ:MNKD - Get Free Report) last released its earnings results on Wednesday, February 26th. The biopharmaceutical company reported $0.03 EPS for the quarter, hitting analysts' consensus estimates of $0.03. MannKind had a net margin of 8.07% and a negative return on equity of 17.74%. The business had revenue of $76.78 million for the quarter, compared to the consensus estimate of $74.99 million. Sell-side analysts forecast that MannKind Co. will post 0.1 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on MNKD. StockNews.com raised shares of MannKind from a "hold" rating to a "buy" rating in a report on Wednesday, March 19th. Mizuho started coverage on MannKind in a research report on Thursday, April 10th. They set an "outperform" rating and a $12.00 price objective for the company. Finally, Wedbush restated an "outperform" rating and set a $11.00 price target on shares of MannKind in a research report on Thursday, February 27th. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $9.56.
View Our Latest Research Report on MannKind
About MannKind
(
Free Report)
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
Further Reading
Before you consider MannKind, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.
While MannKind currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
